Skip to main content
Premium Trial:

Request an Annual Quote

Elazar Rabbani, John Sias, Klaus Hahn, Michael Mancini, John Reed, Frank Young, Vimal Mehta, Terrence Ryan

Premium

Elazar Rabbani, chief executive officer and chairman, and John Sias were re-elected to the board of directors of Enzo Biochem.

Klaus Hahn, an associate professor of cell biology with the Scripps Research Institute, and Michael Mancini, an assistant professor of molecular and cellular biology of Baylor College of Medicine and director of the integrated microscopy core lab, were named to the scientific advisory board of Q3DM of San Diego, a cell-based imaging company.

John Reed, president of the Burnham Institute, has joined the scientific advisory board of Genome BioSciences of Temecula, Calif.

Frank Young, former commissioner of the US Food and Drug Administration, is heading Cosmos Alliance Management, a Washington, DC-based entity he founded in August 2002 to match emerging biotech firms with financial and strategic business partners. The organization recently announced $6.5 million in investments to Panacea Pharmaceuticals of Gaithersburg, Maryland; Sensatex of New York; EluSys Therapeutics of Pine Brook, NY; and Acugen Neuropeutics of Seattle.

Vimal Mehta joins London-based Inpharmatica as senior VP of business development. Previously, Mehta served as senior business development manager at CuraGen, a position he held since 1996.

Terrence Ryan, former director of cell biology at Celera, joins GlaxoSmithKline as director of integrative biology.